Loss of IL-34 Expression Indicates Poor Prognosis in Patients With Lung Adenocarcinoma

Abstract

Interleukin 34 (IL-34), an additional ligand of the colony-stimulating factor-1 receptor (CSF-1R), promotes the secretion of pro-inflammatory cytokines and stimulates NF-κB and JNK-related signaling pathways. However, the potential mechanism and prognostic value of IL-34 in lung adenocarcinoma (LUAD) remain obscure. In this study, IL-34 was found to be downregulated in LUAD tissues compared with para-carcinoma tissues, and loss of IL-34 expression was correlated with shorter overall survival (OS), which was validated by bioinformatics\ analysis in TCGA (The Cancer Genome Atlas) cohort and immunohistochemical analysis in the NTU (Nantong University) cohort, respectively. Subsequently, loss of IL-34 promotes negative regulation of the immune system and inhibits the infiltration of immune cells. Moreover, IL-34 deficiency was shown to be an independent adverse prognostic factor for patients with LUAD, and subgroup analysis indicated that IL-34 might contribute to the stratified management of patients with LUAD. IL-34-based nomogram model significantly improved the accuracy of prognostic predictions for OS of patients with LUAD, both in the TCGA cohort and the NTU cohort. Taken together, our data suggested that loss of IL-34 expression is associated with poor prognosis and negative regulation of the immune system of patients with LUAD, contributing to the stratified management of patients with LUAD.

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset

“…IL-34 plays a controversial role in cancer. In some cancers, IL-34 inhibits cancer cell proliferation and motility, as well as monocyte-like cell differentiation, such as lung cancer ( Wang et al, 2021 ), while it also plays a tumor-promoting role by acting directly on transformed cells to increase their proliferation in a series of cancers ( Franzè et al, 2020 ). Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κB signaling ( Chen et al, 2020 ).…”

Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma

“…If the same gene is detected more than twice, the expression value of the corresponding gene is replaced by its average value. Patients who died on the day of surgery were excluded ( 28 , 29 ). Finally, 50 normal and 365 tumor samples were enrolled in our study.…”

“How Long Have I Got?” in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question

“…In a very recent study, loss of IL-34 expression is associated with poor prognosis and negative regulation of the immune system of patients with pulmonary adenocarcinoma ( 30 ). However, only 18 patients were stage IV, and in these, IL-34 loss and nonloss occurred equally (7/18 and 11/18 patients).…”